PerkinElmer and Immunodiagnostic Systems Holdings have reached an agreement on the terms of a recommended all cash offer whereby PerkinElmer will acquire IDS for approximately £110 million.
The transaction has a total enterprise value of approximately £88 million and is expected to close early in the third quarter of 2021, subject to approvals from the shareholders of IDS, sanction by the High Court of Justice in England and Wales and other customary closing conditions for a public takeover in the United Kingdom.
Through this acquisition, PerkinElmer aims to grow its overall diagnostics business and specifically its immunodiagnostics segment. Moreover, the deal will enable PerkinElmer to combine its channel expertise and testing capabilities with IDS’s chemiluminescence products in endocrinology, autoimmunity and infectious diseases to better serve customers around the world.
IDS’s portfolio and expertise will integrate within EUROIMMUN, a PerkinElmer company since 2017. EUROIMMUN is a specialist in autoimmune testing and an emerging force in infectious disease, allergy and molecular genetic testing.
Wolfgang Schlumberger, CEO of EUROIMMUN, said: “This proposed transaction is highly valuable for both parties as the respective product lines are to a large extent complementary. The co-operation of our global distribution channels, the expansion of the immunoassay portfolio in closely related indication fields and IDS's fully automated random access chemiluminescence platform strengthens our presence in immunodiagnostics. Our customers will benefit from a broader range of assays and laboratory diagnostic workflows. We are excited about these new opportunities and we look forward to welcoming Immunodiagnostic Systems into the PerkinElmer family following the completion of the transaction.”
Headquartered in Boldon, the United Kingdom, IDS is an in-vitro diagnostic solution provider to the clinical laboratory market. IDS develops, manufactures, and markets innovative immunoassays and automated immunoanalyser technologies to provide improved diagnostic outcomes for patients. IDS’s immunoassay portfolio is a combination of an endocrinology specialty testing menu and assay panels in complementary fields. IDS has approximately 300 global employees.
PerkinElmer's global diagnostics portfolio includes solutions focussed on: reproductive health; autoimmune, infectious disease and allergy testing; gene analyses; and genomics offerings for oncology and other molecular tests through its range of instruments, reagents, assay platforms and software offerings.
In terms of financial impact, PerkinElmer expects the acquisition to be modestly accretive to non-GAAP earnings in year-one following the close, and PerkinElmer forecasts IDS’s business to be attractively positioned in markets that are projected to grow at a compound annual growth rate of high-single digits over the next few years.
